Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies 2019


Monitoring Recurrence With Personalized ctDNA Assays

Bernhard Zimmermann, Vice President of Research and Development, Natera

Signatera™ RUO is the first individualized pan-cancer circulating tumor DNA platform. I will be showing results of validation studies for monitoring treatment response, detecting minimal residual disease and predicting disease recurrence. The test detects tumor DNA down to 0.01% VAF (tumor fraction) and data from clinical studies in lung cancer, bladder cancer, colorectal cancer and breast cancer show that ctDNA is detected in plasma of patients up to over one year ahead of clinical detection of relapse.

Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island,